Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique
- PMID: 15743852
- DOI: 10.2106/JBJS.D.02662
Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique
Abstract
Background: Aseptic nontraumatic osteonecrosis of the femoral head is a disorder that can lead to femoral head collapse and the need for total hip replacement. Since osteonecrosis may be a disease of mesenchymal cells or bone cells, the possibility has been raised that bone marrow containing osteogenic precursors implanted into a necrotic lesion of the femoral head may be of benefit in the treatment of this condition. For this reason, we studied the implantation of autologous bone-marrow mononuclear cells in a necrotic lesion of the femoral head to determine the effect on the clinical symptoms and the stage and volume of osteonecrosis.
Methods: We studied thirteen patients (eighteen hips) with stage-I or II osteonecrosis of the femoral head, according to the system of the Association Research Circulation Osseous. The hips were allocated to a program of either core decompression (the control group) or core decompression and implantation of autologous bone-marrow mononuclear cells (the bone-marrow-graft group). Both patients and assessors were blind with respect to treatment-group assignment. The primary outcomes studied were safety, clinical symptoms, and disease progression.
Results: After twenty-four months, there was a significant reduction in pain (p = 0.021) and in joint symptoms measured with the Lequesne index (p = 0.001) and the WOMAC index (p = 0.013) within the bone-marrow-graft group. At twenty-four months, five of the eight hips in the control group had deteriorated to stage III, whereas only one of the ten hips in the bone-marrow-graft group had progressed to this stage. Survival analysis showed a significant difference in the time to collapse between the two groups (p = 0.016). Implantation of bone-marrow mononuclear cells was associated with only minor side effects.
Conclusions: Implantation of autologous bone-marrow mononuclear cells appears to be a safe and effective treatment for early stages of osteonecrosis of the femoral head. Although the findings of this study are promising, their interpretation is limited because of the small number of patients and the short duration of follow-up. Further study is needed to confirm the results.
Similar articles
-
Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study.J Bone Joint Surg Am. 2004 Jun;86(6):1153-60. doi: 10.2106/00004623-200406000-00006. J Bone Joint Surg Am. 2004. PMID: 15173287
-
Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study.Bone. 2011 Nov;49(5):1005-9. doi: 10.1016/j.bone.2011.07.032. Epub 2011 Jul 29. Bone. 2011. PMID: 21821156
-
Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells.Bone. 2012 Jan;50(1):325-30. doi: 10.1016/j.bone.2011.11.002. Epub 2011 Nov 7. Bone. 2012. PMID: 22094904 Clinical Trial.
-
Core decompression combined with autologous bone marrow stem cells versus core decompression alone for patients with osteonecrosis of the femoral head: A meta-analysis.Int J Surg. 2019 Sep;69:23-31. doi: 10.1016/j.ijsu.2019.06.016. Epub 2019 Jul 10. Int J Surg. 2019. PMID: 31301432 Review.
-
The efficacy and safety of core decompression for the treatment of femoral head necrosis: a systematic review and meta-analysis.J Orthop Surg Res. 2019 Sep 11;14(1):306. doi: 10.1186/s13018-019-1359-7. J Orthop Surg Res. 2019. PMID: 31511030 Free PMC article.
Cited by
-
Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study.Musculoskelet Surg. 2013 Dec;97(3):223-8. doi: 10.1007/s12306-013-0273-0. Epub 2013 Jul 14. Musculoskelet Surg. 2013. PMID: 23852661 Clinical Trial.
-
The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.Int Orthop. 2012 Aug;36(8):1583-8. doi: 10.1007/s00264-012-1525-6. Epub 2012 Mar 17. Int Orthop. 2012. PMID: 22426934 Free PMC article.
-
Mesenchymal stem cell-derived microparticles: a promising therapeutic strategy.Int J Mol Sci. 2014 Aug 18;15(8):14348-63. doi: 10.3390/ijms150814348. Int J Mol Sci. 2014. PMID: 25196436 Free PMC article. Review.
-
Combined with Bone Marrow-Derived Cells and rhBMP-2 for Osteonecrosis after Femoral Neck Fractures in Children and Adolescents: A case series.Sci Rep. 2016 Aug 1;6:30730. doi: 10.1038/srep30730. Sci Rep. 2016. PMID: 27477836 Free PMC article. Clinical Trial.
-
Challenges in tissue engineering.J R Soc Interface. 2006 Oct 22;3(10):589-601. doi: 10.1098/rsif.2006.0124. J R Soc Interface. 2006. PMID: 16971328 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical